Moore Capital Management LP Boosts Stake in IQVIA Holdings Inc. $IQV

Moore Capital Management LP lifted its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV) by 588.6% during the 2nd quarter, HoldingsChannel reports. The institutional investor owned 55,756 shares of the medical research company’s stock after acquiring an additional 47,659 shares during the quarter. Moore Capital Management LP’s holdings in IQVIA were worth $10,773,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also bought and sold shares of IQV. International Assets Investment Management LLC bought a new position in shares of IQVIA during the 4th quarter valued at $27,000. Compass Financial Management LLC bought a new stake in shares of IQVIA in the second quarter worth $27,000. Gilpin Wealth Management LLC purchased a new stake in IQVIA during the fourth quarter valued at $27,000. CrossGen Wealth LLC bought a new position in IQVIA in the fourth quarter valued at about $28,000. Finally, Financial Freedom LLC purchased a new position in IQVIA in the first quarter worth about $25,000. Hedge funds and other institutional investors own 89.62% of the company’s stock.

Insiders Place Their Bets

In other news, insider Keriann Cherofsky sold 558 shares of the company’s stock in a transaction dated Wednesday, July 29th. The stock was sold at an average price of $245.21, for a total value of $136,827.18. Following the completion of the transaction, the insider owned 2,989 shares of the company’s stock, valued at $732,932.69. This represents a 15.73% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Bhavik Patel sold 1,855 shares of the stock in a transaction dated Friday, July 31st. The stock was sold at an average price of $235.27, for a total value of $436,425.85. Following the sale, the insider owned 1,348 shares of the company’s stock, valued at $317,143.96. This represents a 57.91% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 12,913 shares of company stock valued at $3,098,793 over the last three months. Insiders own 1.70% of the company’s stock.

IQVIA Stock Performance

IQV opened at $260.48 on Monday. The company has a 50 day simple moving average of $222.14 and a two-hundred day simple moving average of $189.59. The company has a debt-to-equity ratio of 2.18, a current ratio of 0.71 and a quick ratio of 0.71. The firm has a market cap of $42.88 billion, a P/E ratio of 32.32, a PEG ratio of 2.24 and a beta of 1.18. IQVIA Holdings Inc. has a 1-year low of $154.50 and a 1-year high of $265.25.

IQVIA (NYSE:IQV) last announced its quarterly earnings data on Tuesday, July 28th. The medical research company reported $3.15 EPS for the quarter, beating the consensus estimate of $3.03 by $0.12. The firm had revenue of $4.37 billion for the quarter, compared to the consensus estimate of $4.30 billion. IQVIA had a net margin of 8.10% and a return on equity of 30.25%. The company’s revenue was up 8.7% on a year-over-year basis. During the same period last year, the firm earned $2.81 EPS. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. Equities analysts forecast that IQVIA Holdings Inc. will post 11.57 earnings per share for the current fiscal year.

IQVIA declared that its Board of Directors has approved a share repurchase program on Thursday, May 7th that allows the company to repurchase $2.00 billion in shares. This repurchase authorization allows the medical research company to repurchase up to 6.8% of its shares through open market purchases. Shares repurchase programs are often a sign that the company’s leadership believes its stock is undervalued.

Analyst Ratings Changes

Several equities research analysts have recently commented on IQV shares. JPMorgan Chase & Co. upped their price target on shares of IQVIA from $225.00 to $285.00 and gave the company an “overweight” rating in a research report on Wednesday, July 29th. Weiss Ratings upgraded shares of IQVIA from a “hold (c-)” rating to a “hold (c)” rating in a research report on Wednesday, July 15th. Stifel Nicolaus upped their target price on shares of IQVIA from $220.00 to $276.00 and gave the company a “buy” rating in a report on Wednesday, July 29th. BMO Capital Markets lifted their price target on shares of IQVIA from $210.00 to $270.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 29th. Finally, Deutsche Bank Aktiengesellschaft set a $240.00 price objective on shares of IQVIA in a research report on Thursday, July 9th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat, IQVIA presently has an average rating of “Moderate Buy” and a consensus price target of $241.88.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real?world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real?world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.